Moreover, in PD, lower levels of one isoform of apoA1 and tetranectin are reported in the CSF of PD patients compared to control individuals, suggesting that apoA1 is a potential biomarker for PD (Wang et al. 2010). This evidence concerns the gene APOA1 and Parkinson disease.